{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:54:51Z","timestamp":1793328891519,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Positron emission tomography (PET) using small ligands of the fibroblast activation protein (FAP) was recently introduced. However, optimal uptake time has not been defined yet. Here, we systematically compare early (~\u200910\u00a0min p.i.) and late (~\u200960\u00a0min p.i.) FAPI-46 imaging in patients with various types of cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospective single-institutional study. Imaging was performed at the Essen University Hospital, Germany. A total of 69 patients who underwent dual time-point imaging for either restaging (<jats:italic>n<\/jats:italic>\u2009=\u200952, 75%) or staging (<jats:italic>n<\/jats:italic>\u2009=\u200917, 25%) of cancer were included. Patients underwent PET with two acquisitions: early (mean 11\u00a0min, SD 4) and late (mean 66\u00a0min, SD 9). Mean injected activity was 148\u00a0MBq (SD 33).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 400 lesions were detected in 69 patients. Two of 400 (0.5%) lesions were only seen in early time-point imaging but not in late time-point imaging. On a per-patient level, there was no significant difference between SUV<jats:sub>max<\/jats:sub> of hottest tumor lesions (Wilcoxon: <jats:italic>P<\/jats:italic>\u2009=\u20090.73). Organ uptake demonstrated significant early to late decrease in SUVmean (average \u2206SUVmean: \u2212\u20090.48, \u2212\u20090.14, \u2212\u20090.27 for gluteus, liver, and mediastinum, respectively; Wilcoxon: <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). On a per-lesion basis, a slight increase of SUV<jats:sub>max<\/jats:sub> was observed (average \u2206SUV<jats:sub>max<\/jats:sub>: +\u20090.4, Wilcoxon: <jats:italic>P<\/jats:italic>\u2009=\u20090.03).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, early (~\u200910\u00a0min p.i.) versus late (~\u200960\u00a0min p.i.) FAPI-46 imaging resulted in equivalent lesion uptake and tumor detection. For improved feasibility and scan volume, we implement early FAPI-46 PET in future clinical and research protocols.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-021-05266-7","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T09:04:44Z","timestamp":1614071084000},"page":"3221-3227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Equivalent tumor detection for early and late FAPI-46 PET acquisition"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3481-7997","authenticated-orcid":false,"given":"J.","family":"Ferdinandus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hirmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Trajkovic-Arsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zarrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"issue":"10","key":"5266_CR1","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60(10):1421\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.224469.","journal-title":"J Nucl Med"},{"issue":"6","key":"5266_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/1078-0432.CCR-06-1746","volume":"13","author":"LR Henry","year":"2007","unstructured":"Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1746.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5266_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MPA.0b013e31816618ce","volume":"37","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154\u20138. https:\/\/doi.org\/10.1097\/MPA.0b013e31816618ce.","journal-title":"Pancreas"},{"issue":"4","key":"5266_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1365-2559.2009.03399.x","volume":"55","author":"O Dohi","year":"2009","unstructured":"Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, et al. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology. 2009;55(4):432\u201340. https:\/\/doi.org\/10.1111\/j.1365-2559.2009.03399.x.","journal-title":"Histopathology"},{"issue":"9","key":"5266_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.210435.","journal-title":"J Nucl Med"},{"issue":"9","key":"5266_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322. https:\/\/doi.org\/10.2967\/jnumed.118.210443.","journal-title":"J Nucl Med"},{"key":"5266_CR7","doi-asserted-by":"publisher","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2019. https:\/\/doi.org\/10.2967\/jnumed.119.236786.","DOI":"10.2967\/jnumed.119.236786"},{"issue":"8","key":"5266_CR8","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820\u201332. https:\/\/doi.org\/10.1007\/s00259-020-04769-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5266_CR9","doi-asserted-by":"publisher","unstructured":"Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [(68)Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [(18)F]FDG PET\/CT findings. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-04940-6.","DOI":"10.1007\/s00259-020-04940-6"},{"key":"5266_CR10","doi-asserted-by":"publisher","unstructured":"Koerber SA, Staudinger F, Kratochwil C, Adeberg S, Haefner MF, Ungerechts G, et al. The role of FAPI-PET\/CT for patients with malignancies of the lower gastrointestinal tract - first clinical experience. J Nucl Med. 2020. https:\/\/doi.org\/10.2967\/jnumed.119.237016.","DOI":"10.2967\/jnumed.119.237016"},{"key":"5266_CR11","doi-asserted-by":"publisher","unstructured":"Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Fibroblast activation protein targeted PET\/CT with (68)Ga-FAPI for imaging IgG4-related disease: comparison to (18)F-FDG PET\/CT. J Nucl Med. 2020. https:\/\/doi.org\/10.2967\/jnumed.120.244723.","DOI":"10.2967\/jnumed.120.244723"},{"key":"5266_CR12","doi-asserted-by":"publisher","unstructured":"Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, et al. Fibroblast imaging of hepatic carcinoma with (68)Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-04882-z.","DOI":"10.1007\/s00259-020-04882-z"},{"key":"5266_CR13","doi-asserted-by":"publisher","unstructured":"Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-04859-y.","DOI":"10.1007\/s00259-020-04859-y"},{"issue":"9","key":"5266_CR14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1007\/s00259-020-04847-2","volume":"47","author":"J Zheng","year":"2020","unstructured":"Zheng J, Yao S. [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with hepatic cancer. Eur J Nucl Med Mol Imaging. 2020;47(9):2078\u20139. https:\/\/doi.org\/10.1007\/s00259-020-04847-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"5266_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.227967.","journal-title":"J Nucl Med"},{"issue":"4","key":"5266_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/RLU.0000000000002914","volume":"45","author":"Y Luo","year":"2020","unstructured":"Luo Y, Pan Q, Zhang W, Li F. Intense FAPI uptake in inflammation may mask the tumor activity of pancreatic cancer in 68Ga-FAPI PET\/CT. Clin Nucl Med. 2020;45(4):310\u20131. https:\/\/doi.org\/10.1097\/RLU.0000000000002914.","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05266-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05266-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05266-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T05:05:34Z","timestamp":1631077534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05266-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5266"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05266-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. All patients signed written informed consent prior to participation in the study. The authors are responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript. JF had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Justin Ferdinandus has received a Junior Clinician Scientist Stipend granted by the University Duisburg-Essen. Lukas Kessler is a consultant for AAA and BTG and received fees from Sanofi, all outside of the submitted work. Wolfgang P. Fendler is a consultant for Endocyte and BTG, and he received fees from RadioMedix, Bayer, and Parexel outside of the submitted work. Rainer Hamacher is supported by the Clinician Scientist Programm of the University Medicine Essen Clinician Scientist Academy (UMEA) sponsored by the faculty of medicine and Deutsche Forschungsgemeinschaft (DFG). RH has received travel grants from Lilly, Novartis, and PharmaMar as well as fees from Lilly outside of the submitted work. Manuel Weber is on the speakers bureau for Boston Scientific. Lale Umutlu is a speaker for Bayer Healthcare and Siemens Healthcare and has received research grants from Siemens Healthcare outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}